{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=dynamic+susceptibility+contrast-enhanced+magnetic+resonance+imaging",
    "query": {
      "intervention": "dynamic susceptibility contrast-enhanced magnetic resonance imaging"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 19,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=dynamic+susceptibility+contrast-enhanced+magnetic+resonance+imaging&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-11T10:32:20.995Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01996527",
      "title": "3T MRI Biomarkers of Glioma Treatment Response",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Adult Anaplastic Astrocytoma",
        "Adult Anaplastic Ependymoma",
        "Adult Anaplastic Oligodendroglioma",
        "Adult Giant Cell Glioblastoma",
        "Adult Glioblastoma",
        "Adult Gliosarcoma",
        "Recurrent Adult Brain Tumor"
      ],
      "interventions": [
        {
          "name": "3-Tesla magnetic resonance imaging",
          "type": "DEVICE"
        },
        {
          "name": "CEST-MRI",
          "type": "DEVICE"
        },
        {
          "name": "DW-MRI",
          "type": "DEVICE"
        },
        {
          "name": "DCE-MRI",
          "type": "DEVICE"
        },
        {
          "name": "DSC-MRI",
          "type": "DEVICE"
        },
        {
          "name": "IV administration of gadolinium-containing contrast agent",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Vanderbilt-Ingram Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2012-05",
      "completion_date": "2016-01-01",
      "has_results": false,
      "last_update_posted_date": "2017-04-17",
      "last_synced_at": "2026-10-11T10:32:20.995Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01996527"
    },
    {
      "nct_id": "NCT03401866",
      "title": "Multi-site Validation and Application of a Consensus DSC-MRI Protocol",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Glioblastoma Multiforme",
        "Gliosarcoma"
      ],
      "interventions": [
        {
          "name": "DSC-MRI",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "St. Joseph's Hospital and Medical Center, Phoenix",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2018-02",
      "completion_date": "2021-07",
      "has_results": false,
      "last_update_posted_date": "2018-01-17",
      "last_synced_at": "2026-10-11T10:32:20.995Z",
      "location_count": 3,
      "location_summary": "Scottsdale, Arizona • Providence, Rhode Island • Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Providence",
          "state": "Rhode Island"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03401866"
    },
    {
      "nct_id": "NCT02359565",
      "title": "Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Constitutional Mismatch Repair Deficiency Syndrome",
        "Lynch Syndrome",
        "Malignant Glioma",
        "Recurrent Brain Neoplasm",
        "Recurrent Childhood Ependymoma",
        "Recurrent Diffuse Intrinsic Pontine Glioma",
        "Recurrent Medulloblastoma",
        "Refractory Brain Neoplasm",
        "Refractory Diffuse Intrinsic Pontine Glioma",
        "Refractory Ependymoma",
        "Refractory Medulloblastoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Conventional Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Diffusion Tensor Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Diffusion Weighted Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Dynamic Contrast-enhanced MR Perfusion",
          "type": "PROCEDURE"
        },
        {
          "name": "Dynamic Susceptibility Contrast-Perfusion-Weighted Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Spectroscopic Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "1 Year to 30 Years"
      },
      "enrollment_count": 71,
      "start_date": "2015-06-03",
      "completion_date": "2027-01-16",
      "has_results": false,
      "last_update_posted_date": "2026-07-20",
      "last_synced_at": "2026-10-11T10:32:20.995Z",
      "location_count": 11,
      "location_summary": "Los Angeles, California • Palo Alto, California • Aurora, Colorado + 8 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02359565"
    },
    {
      "nct_id": "NCT02526511",
      "title": "Perfusion Magnetic Resonance Imaging in Diagnosing Patients With Kidney Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Stage I Renal Cell Cancer",
        "Stage II Renal Cell Cancer",
        "Stage III Renal Cell Cancer",
        "Stage IV Renal Cell Cancer"
      ],
      "interventions": [
        {
          "name": "Arterial Spin Labeling Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Dynamic Contrast-Enhanced Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Perfusion Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Rutgers, The State University of New Jersey",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 75,
      "start_date": "2015-04",
      "completion_date": "2023-09",
      "has_results": false,
      "last_update_posted_date": "2026-06-02",
      "last_synced_at": "2026-10-11T10:32:20.995Z",
      "location_count": 1,
      "location_summary": "New Brunswick, New Jersey",
      "locations": [
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02526511"
    },
    {
      "nct_id": "NCT00659126",
      "title": "Ferumoxytol- and Gadolinium-Labeled MRI in Measuring Tumors Before or After Treatment in Patients With Primary or Metastatic Brain Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Malignant Neoplasm in the Brain",
        "Primary Brain Neoplasm"
      ],
      "interventions": [
        {
          "name": "3 Tesla Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Dynamic Contrast-Enhanced Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Ferumoxytol",
          "type": "DRUG"
        },
        {
          "name": "Gadolinium",
          "type": "DRUG"
        },
        {
          "name": "High Field Strength Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Susceptibility Weighted Imaging",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "OHSU Knight Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2006-11-16",
      "completion_date": "2020-12-31",
      "has_results": true,
      "last_update_posted_date": "2023-09-07",
      "last_synced_at": "2026-10-11T10:32:20.995Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00659126"
    },
    {
      "nct_id": "NCT00103038",
      "title": "Ferumoxytol in Improving MR Imaging in Patients With High-Grade Brain Tumors or Cerebral Metastases",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Central Nervous System Lymphoma",
        "Malignant Glioma",
        "Metastatic Malignant Neoplasm in the Brain"
      ],
      "interventions": [
        {
          "name": "3 Tesla Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Dynamic Contrast-Enhanced Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Ferumoxytol",
          "type": "DRUG"
        },
        {
          "name": "Gadolinium",
          "type": "DRUG"
        },
        {
          "name": "MRI-Based Angiogram",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "OHSU Knight Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 155,
      "start_date": "2004-06-04",
      "completion_date": "2016-06-10",
      "has_results": true,
      "last_update_posted_date": "2022-06-09",
      "last_synced_at": "2026-10-11T10:32:20.995Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00103038"
    },
    {
      "nct_id": "NCT03115333",
      "title": "DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Gliosarcoma",
        "Recurrent Glioblastoma"
      ],
      "interventions": [
        {
          "name": "Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "ECOG-ACRIN Cancer Research Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 146,
      "start_date": "2017-07-25",
      "completion_date": "2027-05-07",
      "has_results": false,
      "last_update_posted_date": "2026-09-15",
      "last_synced_at": "2026-10-11T10:32:20.995Z",
      "location_count": 58,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Castro Valley, California + 43 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Castro Valley",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03115333"
    },
    {
      "nct_id": "NCT01851733",
      "title": "MRI-Guided Laser Surgery and Doxorubicin Hydrochloride in Treating Patients With Recurrent Glioblastoma Multiforme",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioblastoma"
      ],
      "interventions": [
        {
          "name": "MRI-guided Laser Heat Ablation (MLA)",
          "type": "DEVICE"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Blood draw - dendritic cells",
          "type": "OTHER"
        },
        {
          "name": "Dynamic Susceptibility Contrast Magnetic Resonance Imaging",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 37,
      "start_date": "2013-08-13",
      "completion_date": "2018-05-30",
      "has_results": false,
      "last_update_posted_date": "2021-08-27",
      "last_synced_at": "2026-10-11T10:32:20.995Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01851733"
    },
    {
      "nct_id": "NCT07769918",
      "title": "Hypoxia-targeted Radiotherapy Boost for GBM",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Glioblastoma (GBM)"
      ],
      "interventions": [
        {
          "name": "Dynamic susceptibility contrast MRI (DSC-MRI)",
          "type": "DEVICE"
        },
        {
          "name": "Cercare Medical Neurosuite (CMN) DSC-MRI-derived hypoxia maps",
          "type": "OTHER"
        },
        {
          "name": "Varian TrueBeam",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "OTHER",
        "RADIATION"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2026-09-01",
      "completion_date": "2029-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-18",
      "last_synced_at": "2026-10-11T10:32:20.995Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07769918"
    },
    {
      "nct_id": "NCT02269111",
      "title": "Quantitative MRI in Assessing Disease in Patients With Brain Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Tumors Metastatic to Brain",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "diffusion-weighted magnetic resonance imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "chemical exchange saturation transfer magnetic resonance imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "dynamic contrast-enhanced magnetic resonance imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "dynamic susceptibility contrast-enhanced magnetic resonance imaging",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Vanderbilt-Ingram Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2015-04",
      "completion_date": "2018-05",
      "has_results": false,
      "last_update_posted_date": "2018-05-29",
      "last_synced_at": "2026-10-11T10:32:20.995Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02269111"
    }
  ]
}